2023
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff A, Kaplan L, Frías J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal Of Medicine 2023, 389: 514-526. PMID: 37366315, DOI: 10.1056/nejmoa2301972.Peer-Reviewed Original ResearchConceptsBody weightPercentage changePlacebo groupEnd pointGlucagon-like peptide-1Glucose-dependent insulinotropic polypeptideLower starting doseWeight-related conditionsCommon adverse eventsPlacebo-controlled trialPrimary end pointSecondary end pointsBody mass indexTreatment of obesityDose-dependent increaseDose-response relationshipWeight reductionStarting doseAdverse eventsInsulinotropic polypeptideHeart ratePeptide-1Side effectsGlucagon receptorWeeks
2022
Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux C, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. Obesity 2022, 30: 2340-2350. PMID: 36268562, DOI: 10.1002/oby.23599.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Obesity AgentsBariatric SurgeryHumansKidneyObesityRenal Insufficiency, ChronicConceptsChronic kidney diseaseNational Kidney FoundationManagement of obesityKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action planTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal Of Medicine 2022, 387: 205-216. PMID: 35658024, DOI: 10.1056/nejmoa2206038.Peer-Reviewed Original ResearchConceptsBody weightTreatment discontinuationAdverse eventsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptidePercentage changeDose escalation periodWeight-related complicationsCommon adverse eventsCoprimary end pointsBody mass indexSubstantial global morbidityTreatment of obesityMean percentage changePercentage of participantsMean body weightWeight reductionCardiometabolic measuresTreat populationPlacebo groupWeek 72Mean BMIWeekly dosesDose escalation
2021
Treating the Chronic Disease of Obesity
Gossmann M, Butsch WS, Jastreboff AM. Treating the Chronic Disease of Obesity. Medical Clinics Of North America 2021, 105: 983-1016. PMID: 34688422, DOI: 10.1016/j.mcna.2021.06.005.Peer-Reviewed Original ResearchConceptsChronic diseasesIntensive lifestyle interventionAvailable therapeutic modalitiesPrimary care providersTreatable chronic diseaseCare of patientsAntiobesity pharmacotherapiesBariatric surgeryLifestyle interventionSafe therapyComprehensive careTherapeutic modalitiesCare providersTreatment approachesObesityPatientsDiseaseCarePharmacotherapySurgeryTherapyDiagnosis